NCT07292909RecruitingPhase 4
Effect of Empagliflozin on Inflammation
Randomized Trial to Evaluate the Anti-inflammatory Effects of Empagliflozin Following PCI
Source: ClinicalTrials.gov · Last updated 18 Dec 2025
Brief summary (registry, in English)
Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure. The exact mechanism of this effect is currently not clearly understood. He hypothesize that empagliflozin has other properties than glucose lowering, that can explain its efficacy. One of these properties, is an anti-inflammatory effect. To document this, we are using a model of inflammation following percutaneous coronary scenting. We know that patients who get a stent will develop inflammation following stenting. This is documenting by a higher level of C-Reactive Protein 24 hours after the procedure. Patients who will participate in the study, will receive empagliflozin or a placebo tablet for 3 days prior to the revascularisation procedure. CRP and other inflammatory markers will be measured before intervention and 24 hours later. The goal is to demonstrate a lower rise in CRP following intervention in patients treated with empagliflozin vs. those who have received a placebo.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 6 Dec 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Hotel Dieu de France Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07292909
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 1 Sept 2025 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- • Patients who have been taking an SGLT-2 inhibitor during the last month
- Patients who are receiving any anti-inflammatory medication: immunosuppressor, steroids, NSAID…
- Patients who have underlying inflammatory conditions such as rheumatic arthritis, infection, active malignancy
- Patients with an acute coronary syndrome within the last month
- Intervention on a restenotic lesion or lesion in a saphenous vein graft
- Creatinine clearance less than 30 mL/min
- Patients who are treated with devices other than balloons and stents (lithotripsy, rotational atherectomy…)
Who the study is looking for
- • Patients with stable CAD who are electively scheduled for PCI on a de novo lesion in a native coronary artery
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hotel Dieu de France Coordinator of this site? Confirm its status | Beirut | Lebanon | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.